Skip to main content
logo
Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
3.830
+0.020 (0.52%)
Sep 25, 2026, 4:00 PM EDT - Market closed

Relmada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
40935416125105625
Market Cap Growth
637.45%2157.41%-87.41%18.63%-83.18%19.93%
Enterprise Value
191340-3818-79537
Last Close Price
3.834.830.524.143.4922.53

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
1.984.090.441.460.753.00
P/TBV Ratio
1.984.090.441.460.753.00

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Debt / Equity Ratio
-1.05-1.07-1.26-1.13-1.06-1.02
Net Debt / EBITDA Ratio
----0.921.69
Net Debt / FCF Ratio
4.732.030.871.871.432.31
Quick Ratio
29.3414.464.367.9011.9414.08
Current Ratio
29.5214.624.458.0012.2614.83
Return on Equity (ROE)
-55.66%-94.05%-132.33%-87.51%-90.07%-80.14%
Return on Assets (ROA)
-32.39%-50.24%-73.14%-51.76%-53.57%-46.01%
Return on Capital Employed (ROCE)
-29.40%-64.20%-236.10%-121.50%-114.80%-60.40%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-15.16%-16.20%-509.73%-79.28%-149.50%-20.13%
FCF Yield
-11.26%-12.93%-329.85%-41.46%-98.81%-14.71%
Buyback Yield / Dilution
-136.32%-30.89%-0.21%-1.59%-68.80%-12.56%
SEC Filings: 10-K · 10-Q